Shanghai, China,August 20, 2026
Henlius announced its 2026 interim results, highlighting continued financial growth, expanding global commercialization, and progress across its innovative and biosimilar pipelines. During the first half of 2026, the company reported RMB 3.5882 billion in revenue, representing a 27.3% year-over-year increase, while net profit reached RMB 430.4 million, up 10.3% year over year. Non-IFRS profit increased 46.7% to RMB 572.3 million, while adjusted EBITDA reached RMB 904.1 million, an increase of 35.2%. The company attributed the performance to sustained global commercialization of its core products and integrated operations across research, development, manufacturing and commercial activities. Henlius said the results support its ongoing transformation toward a China-headquartered multinational biopharmaceutical company, or C-MNC.
Global Commercialization Strengthens Product Portfolio
Henlius continued to expand the international reach of its marketed medicines during the reporting period. The company reported that 10 products have received approvals across more than 60 countries and regions, benefiting more than 1.1 million patients worldwide. Global product sales revenue reached RMB 2.9386 billion, up 14.9% year over year. Particularly notable was the performance outside China, where ex-China sales revenue increased 159.4% to RMB 105.3 million, while ex-China product profit reached RMB 59.5 million. The company’s breast cancer portfolio remained an important contributor to growth, generating RMB 1.6983 billion in global sales revenue during the first half. HANQUYOU (trastuzumab), HANBEIYOU (pertuzumab), HANNAIJIA (neratinib) and fovinaciclib contributed to the portfolio’s performance. During the period, HANBEIYOU received marketing authorizations from the European Commission and China’s NMPA, adding to its U.S. approval and expanding Henlius’ global HER2-targeted treatment portfolio. In oncology, serplulimab generated RMB 597.5 million in global sales revenue. The medicine received approval in China for perioperative treatment of gastric cancer and obtained additional first-line indications in the European Union for non-squamous non-small cell lung cancer, esophageal squamous cell carcinoma and squamous non-small cell lung cancer. Serplulimab has now secured approvals in more than 50 countries and regions, supporting Henlius’ international commercialization strategy.
Innovation Pipeline Advances Across Cancer Research
Henlius is also increasing investment in its innovative drug pipeline, with research and development expenditure reaching RMB 1.4507 billion, a 45.7% year-over-year increase. The company has established technology platforms spanning next-generation immuno-oncology, Hanjugator ADCs, multi-specific T-cell engagers and artificial intelligence, with more than 50 early-stage pipeline molecules across oncology, immunology and inflammation, neuroscience and metabolic diseases. Among the company’s key pipeline candidates, HLX43, a potential broad-spectrum PD-L1 antibody-drug conjugate, is being evaluated across multiple solid tumors. International Phase 2 and Phase 2/3 studies are progressing in regions including China, Europe, the United States, Japan and Australia. More than 1,500 patients have been enrolled globally across studies evaluating HLX43 as monotherapy or in combination regimens. Other candidates are also progressing through clinical development. Dulpatatug (HLX22) is being evaluated in international studies for HER2-positive gastric and breast cancers, while additional assets including HLX87, HLX97, HLX49 and HLX316 are advancing through development. Henlius also plans to submit IND applications for several early-stage candidates during the second half of 2026.
Advertisement
Globalization 2.0 Expands R&D and Manufacturing
Henlius is strengthening its Globalization 2.0 strategy through internal commercialization capabilities and strategic partnerships. The company has established international teams across Europe, the United States, Japan and Australia, with clinical studies underway in nearly 30 countries and regions involving more than 1,000 clinical research centers. During the first half of 2026, Henlius received 32 new clinical trial approvals and 25 marketing authorizations worldwide. The company also reported more than 1,400 GMP commercial production batches completed to date and more than 100 regulatory and partner inspections and audits passed with a reported 100% pass rate. Nine first commercial shipments and 18 batch shipments were completed to ex-China markets during the period. Henlius said its integrated R&D, clinical development, regulatory, manufacturing and commercialization capabilities are supporting the continued expansion of its global business. Looking toward 2030, the company aims to bring 10 new products to markets worldwide, with more than five expected to reach European and U.S. markets, reinforcing its ambition to become a globally influential innovative biopharmaceutical company.
Source: Henlius press relese
